ClearPoint Neuro (CLPT) Change in Accured Expenses (2011 - 2026)

ClearPoint Neuro (CLPT) has 15 years of Change in Accured Expenses data on file, last reported at -$437000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 84.84% year-over-year to -$437000.0; the trailing twelve-month figure through Mar 2026 stood at -$5.1 million (down 539.77% YoY), and the FY2025 full-year result was -$7.5 million, down 342.19% from the prior year.
• Change in Accured Expenses grew to -$437000.0 in Q1 2026, from -$6.3 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.7 million in Q4 2024 to a low of -$6.3 million in Q4 2025.
• A 5-year average of -$230000.0 and a median of $374000.0 in 2023 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 443.4% in 2022, while the deepest fall reached 1181.48% in 2022.
• Tracing CLPT's Change in Accured Expenses over 5 years: stood at $336000.0 in 2022, then gained by 11.31% to $374000.0 in 2023, then surged by 363.1% to $1.7 million in 2024, then plunged by 461.95% to -$6.3 million in 2025, then jumped by 93.03% to -$437000.0 in 2026.
• Business Quant data shows CLPT's Change in Accured Expenses at -$437000.0 in Q1 2026, -$6.3 million in Q4 2025, and $693000.0 in Q3 2025.